- Home
- CELC vs GMRE Comparison
CELC vs GMRE Comparison
Compare CELC & GMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- GMRE
- Stock Information
- Founded
- CELC 2011
- GMRE 2011
- Country
- CELC United States
- GMRE United States
- Employees
- CELC N/A
- GMRE N/A
- Industry
- CELC Medical Specialities
- GMRE Real Estate Investment Trusts
- Sector
- CELC Health Care
- GMRE Real Estate
- Exchange
- CELC Nasdaq
- GMRE Nasdaq
- Market Cap
- CELC 440.0M
- GMRE 446.7M
- IPO Year
- CELC 2017
- GMRE N/A
- Fundamental
- Price
- CELC $51.79
- GMRE $6.66
- Analyst Decision
- CELC Strong Buy
- GMRE Buy
- Analyst Count
- CELC 6
- GMRE 3
- Target Price
- CELC $46.50
- GMRE $10.38
- AVG Volume (30 Days)
- CELC 2.9M
- GMRE 642.9K
- Earning Date
- CELC 08-14-2025
- GMRE 08-05-2025
- Dividend Yield
- CELC N/A
- GMRE 9.00%
- EPS Growth
- CELC N/A
- GMRE N/A
- EPS
- CELC N/A
- GMRE 0.07
- Revenue
- CELC N/A
- GMRE $141,896,000.00
- Revenue This Year
- CELC N/A
- GMRE $4.47
- Revenue Next Year
- CELC N/A
- GMRE $3.60
- P/E Ratio
- CELC N/A
- GMRE $99.40
- Revenue Growth
- CELC N/A
- GMRE 2.95
- 52 Week Low
- CELC $7.58
- GMRE $6.06
- 52 Week High
- CELC $53.70
- GMRE $10.46
- Technical
- Relative Strength Index (RSI)
- CELC 92.18
- GMRE 45.56
- Support Level
- CELC $38.00
- GMRE $6.44
- Resistance Level
- CELC $53.40
- GMRE $7.08
- Average True Range (ATR)
- CELC 3.33
- GMRE 0.25
- MACD
- CELC 0.92
- GMRE -0.01
- Stochastic Oscillator
- CELC 89.44
- GMRE 48.54
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About GMRE Global Medical REIT Inc.
Global Medical REIT Inc is engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.